SynthesisMolecular psychiatry2026
Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundL-theanine, an amino acid derived from green tea, has been suggested to alleviate affective symptoms and enhance cognitive performance, but its clinical relevance remains uncertain.
methodsWe conducted a systematic review and meta-analysis of 31 randomised controlled trials (n = 1168) comparing oral L-theanine with placebo in healthy and clinical populations. The primary outcome was the acute effect of a single dose on stress in healthy adults. Secondary outcomes included clinical measures (stress after repeated dosing, anxiety, depressive symptoms, and fatigue) and cognitive measures (reaction times and attention tasks with single and repeated doses). Safety was assessed by comparing dropout rates and reasons between L-theanine and placebo groups.
resultsA single 200 mg dose taken 30-60 min before cognitive testing significantly improved choice reaction time (Standardised Mean Difference [SMD] = 0.51; 95% CI, 0.25-0.77), indicating enhanced attention. The reduction in acute stress was modest (SMD = 0.31) and largely influenced by studies with a high risk of bias. No significant effect on fatigue was observed. Excluding one outlier, a significant reduction in depressive symptoms following a single dose in healthy individuals was found (SMD = 0.69; 95% CI, 0.13-1.25) with low heterogeneity. Anxiety effects were inconsistent and non-significant except for one study on psychotic anxiety (SMD = 0.54; 400 mg/day for 8 weeks). No serious adverse events were reported.
conclusionsL-theanine is safe and shows a robust short-term benefit on attention in healthy adults, with a potential antidepressant effect warranting confirmation in high-quality trials, especially in clinical populations.
Identifiers
42410082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.